What is Optovue?
Operating under the Visionix umbrella, Optovue specializes in the development of high-precision diagnostic, screening, and refraction equipment. By integrating advanced technologies such as Optical Coherence Tomography (OCT) systems and automated lens finishing tools, the firm provides essential infrastructure for optometrists and ophthalmologists. The company's market position is defined by its ability to streamline clinical workflows while enhancing diagnostic accuracy, serving a broad spectrum of clients ranging from independent optometry practices to large-scale optical retail chains. Through its focus on intuitive, high-performance hardware, Optovue remains a critical partner in the global eye care ecosystem, bridging the gap between complex clinical data and actionable patient care solutions.
How much funding has Optovue raised?
Optovue has raised a total of $12.5M across 2 funding rounds:
Series B
$10.5M
Debt
$2M
Series B (2007): $10.5M with participation from iD SoftCapital Group, Trevi Health Ventures, and Acorn Campus
Debt (2021): $2M led by PPP
Key Investors in Optovue
iD SoftCapital Group
iD Ventures America is an investment firm that focuses on identifying and investing in North American companies characterized by visionary innovation and strong growth potential.
Trevi Health Ventures
Trevi Health Capital is a specialist investment firm that provides healthcare-focused alternative asset management with an emphasis on medical devices and biopharmaceuticals.
Acorn Campus
Acorn Campus Ventures is a venture fund with incubation facility and infrastructure, focusing on the wireless, semiconductor, photonics, and life science fields.
What's next for Optovue?
With the support of its latest capital injection, Optovue is well-positioned to scale its R&D initiatives and expand its footprint in the competitive medical device sector. The strategic focus will likely shift toward integrating artificial intelligence into its existing diagnostic platforms to further automate refraction and screening processes. By leveraging its established network and the expertise of its long-term financial partners, the company is poised to capitalize on the increasing demand for digital health solutions in ophthalmology. Future growth will likely be driven by the continued adoption of its next-generation OCT systems and the optimization of its global supply chain, ensuring that practitioners have access to the most reliable and efficient tools available in the modern clinical environment.
See full Optovue company page
